RYTHM (RYM) versus Its Competitors Head to Head Comparison

RYTHM (NASDAQ:RYMGet Free Report) is one of 903 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare RYTHM to related companies based on the strength of its institutional ownership, profitability, earnings, valuation, analyst recommendations, dividends and risk.

Risk & Volatility

RYTHM has a beta of 9.44, suggesting that its stock price is 844% more volatile than the S&P 500. Comparatively, RYTHM’s rivals have a beta of -3.18, suggesting that their average stock price is 418% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for RYTHM and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RYTHM 1 0 0 0 1.00
RYTHM Competitors 7576 13627 25429 997 2.42

As a group, “Pharmaceuticals” companies have a potential upside of 32.68%. Given RYTHM’s rivals stronger consensus rating and higher probable upside, analysts plainly believe RYTHM has less favorable growth aspects than its rivals.

Profitability

This table compares RYTHM and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RYTHM -6.20% -12.57% -2.60%
RYTHM Competitors -2,309.62% -222.80% -17.20%

Valuation & Earnings

This table compares RYTHM and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
RYTHM $17.28 million -$33.26 million -2.20
RYTHM Competitors $3.48 billion $3.12 billion 543.71

RYTHM’s rivals have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

6.0% of RYTHM shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

RYTHM rivals beat RYTHM on 9 of the 13 factors compared.

RYTHM Company Profile

(Get Free Report)

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

Receive News & Ratings for RYTHM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RYTHM and related companies with MarketBeat.com's FREE daily email newsletter.